Samuel Jones IV, MD’s concerns about private equity’s expansion to cardiology.

Cardiology Practices

Private Equity’s Cardiovascular Expansion

Private equity’s massive expansion across US healthcare has largely skipped cardiology, but a new JAMA paper suggests that cardiovascular clinicians should expect PE to have a much greater influence within their specialty going forward.

Over the last decade private equity firms spent over $750B acquiring healthcare organizations, with annual investments surging from $41.5B in 2010 to $119.9B in 2019.

Those investments often went to hospital systems and practices within key medical specialties like radiology and dermatology. However, new market factors are driving PE’s increased interest in cardiovascular groups:

• CVD is expensive, driving $407B in annual costs in the US between 2018-2019.
• The transition to outpatient and value-based care suggests that more of that money could flow to practices with the right strategies and capabilities.
• Practices with Ambulatory Surgery Centers (ASCs) are becoming particularly attractive, as CMS added 23 ASC cardiac catheterization and PCI codes in just the last two years.
• Many of the 3k cardiology practices across the US make for attractive regional “roll-up” acquisition targets for PE.

There are pros and cons to PE’s expected cardiology expansion. PE provides smaller or struggling cardiovascular practices with the capital needed to support operations and achieve scale in the face of major challenges (i.e. clinician shortages, the VBC shift), while giving practice partners attractive payouts. However, there’s also a long list of concerns.

• Private equity acquisitions have shown to drive up the cost of care, especially when a PE-owned group controls a large share of a local market.
• PE ownership has been known to lead to compensation and working condition challenges for practice employees.
• Previous studies have shown that PE ownership hurts care quality and outcomes.

So how and when are all these PE-driven cardiology practice acquisitions going to take place? There are already at least 12 PE firms targeting cardiology, and at least six major acquisition-focused cardiovascular practice platforms. These PE-owned practices made at least nine acquisitions between January and June 2023, nearly matching 2021 and 2022’s full-year totals (10 & 11), while far surpassing 2018 through 2020 (6 in 3yrs). 

Those are small numbers compared to other specialties, but they could be rising fast.

The Takeaway

Cardiology practices have largely avoided PE’s expansion across healthcare so far, but that could change over the coming years, and at least according to this paper, it would bring more challenges than benefits.

HeartFlow’s FFRCT Milestone

HeartFlow had reason to celebrate as it entered 2024, surpassing 250,000 patients examined with its FFRCT Analysis solution, while helping to avoid a huge number of unnecessary invasive angiographies.

From CPACS to CVIS

Cardiovascular imaging has come a long way from CPACS. Explore the evolution of cardiology image and data management in this Merge by Merative executive brief, and see what makes CVIS such a significant advancement.

Experience the Future of Learning: Medtronic Academy 2.0 is Here!

Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!

The Wire

• Echo AI’s RHD Impact: The Washington Post put a spotlight on how handheld ultrasound systems and AI algorithms might significantly improve early detection of rheumatic heart disease, especially in developing countries. The article detailed a new echo AI solution developed by Children’s National and Us2.ai that could help detect pediatric RHD while it’s still easily treatable with penicillin (currently 90% accuracy), potentially avoiding thousands of heart surgeries and RHD deaths. The researchers will initially deploy the echo AI solution in a Ugandan screening program that will also be used to further train the algorithm.

• T-TEER Benefits: Patients with severe tricuspid regurgitation (TR) are generally healthier after they’ve undergone tricuspid transcatheter edge-to-edge repair (T-TEER) with Abbott’s TriClip system compared to those that only received standard medical therapy. Researchers randomized 350 patients with severe TR to receive either T-TEER or medical therapy, and then assessed their health status using the Kansas City Cardiomyopathy Questionnaire. The T-TEER group saw greater health status improvements at one month through one year (mean between-group difference: 10.4 pts) and were more likely to be “alive and well” at one year (74.8% vs 45.9%). 

• Rock Health’s 2023 Recap: Rock Health’s 2023 digital health funding numbers are in, and they’re every bit as bleak as expected, with funding falling to $10.7B across 492 rounds. That represents a significant drop from 2022 and 2021 ($15.3B & $29.1B), and it’s the lowest annual number since 2019. However, Rock Health reassured that these declines will strengthen the sector in the long run (i.e. fewer but stronger companies, platform synergies via M&A, and more successful IPOs). Check out our full writeup in Digital Health Wire for the details.

• HPD Breakthrough: New findings published in JAMA Cardiology provide insight into how hypertensive disorders of pregnancy (HPD) arise and how they might be treated or even prevented. Researchers analyzed genetic data from over 600k individuals, identifying six crucial proteins involved in inflammation and CV processes that likely contribute to or protect against HPD: CD40, galectin-3, cystatin B, eosinophil cationic protein, heat shock protein 27, and NT-proBNP.

• Ultromics and Pfizer’s Amyloidosis Alliance: Echo AI company Ultromics announced a partnership with Pfizer that will support the development and FDA clearance of Ultromics’s echo AI algorithm for cardiac amyloidosis detection. Ultromics’ EchoGo Amyloidosis AI solution analyzes routine echocardiograms to identify patients with cardiac amyloidosis, and gained FDA Breakthrough Device Designation in 2023. The alliance is another example of pharma companies partnering with AI developers to improve detection of treatable patients, following similar partnerships between Anumana and Pfizer (ECG AI for cardiac amyloidosis) and Viz.ai and BMS (ECG AI for HCM).

• SGLT-2is Boost Diabetes & Kidney Outcomes: In a study using data from roughly 230k global patients, the use of SGLT2 inhibitors in patients with type 2 diabetes and acute kidney injury was linked to significantly lower risks for mortality (–31%), major adverse kidney events (–38%) and major adverse cardiovascular events (–25%). However, SGLT-2is were only prescribed to 2.3% of patients with T2D and AKD, suggesting that more education is needed about the drug group’s benefits for this population.

• Cardiac Health’s Rural Road Trip: In the federally funded RURAL project, researchers have turned a mobile coach into an exam room on wheels, leveraging a mobile CT scanner and laboratory to study why rural health outcomes are so poor. The RURAL project team will perform cardiac and lung CT exams, along with blood pressure, cholesterol, and blood sugar tests across 10 rural counties in the southeastern US, with the goal of testing up to 4.6k individuals.

• Stay Active During Young Adulthood: New research highlights the benefits of sustained physical activity during young adulthood for reducing CV events later in life. The study categorized 2,902 participants based on their long-term exercise consistency, measured as time-in-target rage (TTR). Findings revealed that maintaining at least 75% TTR lowers the risk of CV events by 40% compared to the lowest TTR group (HR: 0.6), emphasizing the importance of consistent exercise during early adult years. 

• Nanowear’s BP Clearance: Remote diagnostics company Nanowear announced the FDA 510(k) Clearance of its SimpleSense-BP continuous blood pressure monitor and hypertension diagnostics system. The cuffless wearable undergarment uses AI and nanosensors to capture 85+ biomarkers, and is validated to continuously track and report changes in systolic and diastolic blood pressure (> +/- 15mmHg  & +/- 10mmHg) for all classes of hypertension.

• GLP-1s and Suicidal Ideation: As if GLP-1s didn’t already have enough going for them, a study in Nature Medicine added another tailwind after finding that they’re also associated with a lower risk of suicidal ideation than alternative weight loss medications. Looking at EHR data for over 240k overweight patients and 1.6M patients with type 2 diabetes, semaglutide was associated with a 49% to 73% lower risk of suicidal ideation compared to those taking other treatments. Novo Nordisk and Eli Lilly each naturally issued statements saying they were thrilled with the results.

• New Data Supports Hospital-at-Home: An observational study in the Annals of Internal Medicinehighlighted significant benefits of the Acute Hospital Care at Home waiver program for 5,100 socially vulnerable / medically complex patients that were monitored from July 2022 to June 2023. Despite many of the participants having conditions such as heart failure (43%) and chronic lung disease (43%), those who received hospital-at-home care saw overall low mortality (0.5%), less use of skilled nursing facilities (3%), and lower rehospitalization rates (6%) – regardless of race, ethnicity, or dual eligibility.

AHA Honors Stanford & Bunkerhill’s Incidental CAC Paper

Stanford University’s paper exploring how Bunkerhill’s incidental CAC algorithm increased statin use won the American Heart Association’s 2023 Willerson Award for the best clinical paper published in Circulation this year. See how Bunkerhill’s incidental CAC impacted patient care here.

Reducing ECG Background Noise

Monebo’s Kinitec Rhythms ECG Algorithm separates true ECG signals from background noise, leading to more accurate diagnoses and improved operator efficiency. See for yourself how the algorithm measured up to a gold standard.

The Resource Wire

• Where to Go for Cardio AI? TeraRecon’s Cardio Suite is a collection of hand-selected, vendor-neutral Cardiology AI algorithms that aid in the analysis and interpretation of echocardiograms and chest CTs. Learn about TeraRecon’s AI offering and how they improve efficiency and accuracy here.

• AI-Powered Home Ultrasound: The recently published CUMIN study shows the technical feasibility of AI-POCUS in the hands of novice nurses and opens new possibilities for redefining how we approach cardiac care. Learn more in this Us2.ai report. 

• Start Measuring What Matters: Looking to optimize your cardiovascular imaging services, but don’t know what to measure? Check out this Change Healthcare report for insights on how to track and evaluate your cardiovascular imaging performance, assess quality, and enhance operational efficiency. Read the full article now and start measuring what matters!

• The Holy Grail of Prevention: For years, world-renowned prevention expert Dr. Arthur Agatston, author of The South Beach Diet and developer of the “Agatston Score,” had been looking for technology that could accurately identify all types of plaque in the heart. Then, he was introduced to Cleerly. Hear from Dr. Agatston on why he believes “Cleerly really is the holy grail of prevention.”

• Relieving The Burden of Post-Processing: With the advent of advanced imaging technologies like CCTA come added burdens to technologists and diagnostic imaging centers. See how PIA can relieve the burden of post-processing, saving you time while helping your bottom line.